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Background: Hand-held NB-UVB units are lightweight devices that may overcome the need to treat vitiligo in
hospital-based phototherapy cabinets, allowing early treatment at home that may enhance the likelihood of
successful repigmentation. The pilot Hi-Light trial examined the feasibility of conducting a large multi-centre
randomised controlled trial (RCT) on the use of such devices by exploring recruitment, adherence, acceptability,
and patient education.
Methods: This was a feasibility, double-blind, multi-centre, parallel group randomised placebo-controlled trial of
hand-held NB-UVB phototherapy for the treatment of vitiligo at home. The overall duration of the trial was seven
months; three months recruitment and four months treatment. Participants were randomly allocated to active or
placebo groups (2:1 ratio). The primary outcome measure was the proportion of eligible participants who were
willing to be randomised. The secondary outcomes included proportion of participants expressing interest in the
trial and fulfilling eligibility criteria, withdrawal rates and missing data, proportion of participants adhering to and
satisfied with the treatment, and incidence of NB-UVB short-term adverse events.
Results: Eighty-three percent (45/54) of vitiligo patients who expressed interest in the trial were willing to be
randomised. Due to time and financial constraints, only 29/45 potential participants were booked to attend a
baseline hospital visit. All 29 (100%) potential participants were confirmed as being eligible and were subsequently
randomised. Willingness to participate in the study for General Practice (family physicians) surgeries and hospitals
were 40% and 79%, respectively; 86% (25/29) of patients adhered to the treatment and 65% (7/11) of patients in
the active group had some degree of repigmentation. Only one patient in the active group reported erythema
grade 3 (3%). Both devices (Dermfix 1000 NB-UVB and Waldmann NB-UVB 109) were acceptable to participants.
Conclusions: Hand-held NB-UVB devices need evaluation in a large, pragmatic RCT. This pilot trial has explored many
of the uncertainties that need to be overcome before embarking on a full scale trial, including the development of a
comprehensive training package and treatment protocol. The study has shown strong willingness of participants to be
randomised, very good treatment adherence and repigmentation rates, and provided evidence of feasibility for a
definitive trial.
Trial registration: NCT01478945
Keywords: Hand-held phototherapy, Home phototherapy, Patient education, Randomised trial, Vitiligo* Correspondence: viktoria.eleftheriadou@nottingham.ac.uk
1Centre of Evidence Based Dermatology, University of Nottingham, Kings
Meadow Campus, Lenton Lane, Nottingham NG7 2NR, UK
Full list of author information is available at the end of the article
© 2014 Eleftheriadou et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Eleftheriadou et al. Trials 2014, 15:51 Page 2 of 12
http://www.trialsjournal.com/content/15/1/51Background
Vitiligo is the most common depigmentation disorder of
the skin affecting around 0.5% of the population world-
wide. The British Association of Dermatologists clinical
guidelines for the management of vitiligo recommend
narrow-band ultraviolet light B (NB-UVB) (311 to 312 nm),
tacrolimus, and topical steroids to treat the condition [1].
The Cochrane systematic review update concluded that
light combination interventions were superior to mono-
therapies [2]. However, larger studies are needed to provide
stronger evidence for the many combination interventions
that have shown promise in treating vitiligo [2].
Evidence suggests that early treatment of vitiligo may in-
crease the possibility of successful repigmentation even on
the most resistant areas such as hands. In early stages of
vitiligo, some functioning melanocytes are still present, pro-
viding a possible explanation of these results [3-5]. Recently,
a new European Guideline for vitiligo was published, sug-
gesting early treatment of small lesions of recent onset and
childhood vitiligo with combination of phototherapy and
topical agents [6]. However, suitable facilities and equipment
are needed if this new guideline is to be implemented.
Phototherapy for the treatment of vitiligo
NB-UVB is available in secondary care, requires regular
hospital visits, and usually involves whole body cabinets
suitable for extensive vitiligo [1]. Currently, there are vari-
ous devices available on the market for the delivery of NB-
UVB: whole body units, hand and feet units, and hand-
held units. The choice of devices is usually based on the
size and location of the lesions and the percentage of the
body surface affected [7]. Hand-held NB-UVB units are
portable and light weight devices, suitable for the treat-
ment of small areas of skin. Benefits of using hand-held
devices at home include the reduction in number of hos-
pital visits, sparing of uninvolved skin, fewer costs for pa-
tients (such as travelling costs), and the ability to treat at
an early stage of the disease when the intervention might
be more effective [8].
Although there are currently no studies evaluating
hand-held NB-UVB devices for vitiligo, participants have
reported benefit [9]. Further, trials using these devices for
home treatment of scalp psoriasis have shown that they
are effective, well tolerated, easy to use, and safe [10,11].
The effectiveness and safety of NB-UVB for the treatment
of vitiligo has been identified to be an important research
topic for both patients and clinicians [12]. Feedback from
patients (via the Vitiligo Society UK and Vitiligo Support
International) suggests that patients are currently buying
hand-held NB-UVB units and using them at home un-
supervised. Moreover, if hand-held devices prove to be ef-
fective and safe for the treatment of vitiligo at home, this
could be an important addition to the treatment options
available to patients with focal or early vitiligo.Objectives
The main aim of this pilot trial was to determine the feasi-
bility of conducting a national, multi-centre, randomised
controlled trial (RCT) to determine the effectiveness and
safety of home hand-held NB-UVB phototherapy units
both compared to and in combination with topical treat-
ments for repigmentation of early and/or focal vitiligo. The
primary objective of this pilot trial was to establish the pro-
portion of eligible patients with vitiligo who are willing to
be randomised to home NB-UVB (number of randomised
participants/number of eligible participants at baseline). In
this trial, two different hand-held NB-UVB devices, Derm-
fix 1000 NB-UVB and Waldmann NB-UVB 109, with the
same output, but differing with regards to the size of treat-
ment area, weight of the unit, cable length, and price were
tested. The rationale behind using two different devices was
to monitor and assess which of the two units was best toler-
ated in terms of participant satisfaction. The information
gathered assisted in the choice of device for the main RCT.
An innovative training package was developed for par-
ticipants explaining how to use the intervention and how
to deal with side effects. The successfulness of this training
package was established by measuring the following sec-
ondary objectives: i) preparation of a training package for
participants explaining how to use the intervention and
how to deal with possible side effects; ii) estimation of
withdrawal rates and missing data; iii) establishment of
participants’ adherence to and satisfaction with the treat-
ment; and iv) establishment of the occurrence of possible
short-term side effects, i.e., if the device is suitable for
home use with limited medical supervision.
Another secondary objective of this pilot trial was the
testing of feasibility outcomes for the main RCT including
repigmentation, cessation of spreading of the disease, im-
pact on quality of life, global improvement in vitiligo, pa-
tient’s benefit index, and colour match.
Methods
Ethics approval
This trial was approved by the National Research Ethics
Service committee of East Midlands (REC reference: 11/
EM/0331) and was registered with clinicaltrials.gov
(ISRCTN: NCT01478945).
Trial configuration
This was a feasibility, double-blind, multi-centre, parallel
group randomised placebo-controlled trial of hand-held
NB-UVB phototherapy for the treatment of vitiligo at
home. The acronym for this trial was HI-Light trial for viti-
ligo (Home Intervention of Light therapy trial for vitiligo).
The overall duration of the trial was seven months: a three-
month recruitment period (1st of March 2012 to 31st of
May 2012) and a four-month treatment period (until 31st
of September 2012).
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Centre and NHS Treatment Centre in Nottingham, and
at Leicester Royal Infirmary in Leicester. Primary Care
Research Networks in both Leicester and Nottingham
were involved. King’s Mill Hospital in Mansfield and
local GP practices (Nottingham and Leicester) were used
as participant identification centres along with direct ad-
vertising to participants through the Vitiligo Society UK
and the Centre of Evidence Based Dermatology.
Randomisation and blinding
Participants were randomly allocated to an active or
placebo group in a 2:1 ratio. Participants in the active
group were allocated to two different hand-held de-
vices, Dermfix 1000™ and Waldmann™, in a 1:1 ratio.
The randomisation was based on a computer generated
pseudo-random code, using random permuted blocks
of randomly varying size, created by the Nottingham
Clinical Trials Unit in accordance with their standard
operating procedure and held on a secure University of
Nottingham server. The randomisation was stratified by
the recruiting site (Nottingham and Leicester). Partici-
pants, research nurses, dermatologists, and independent
outcome assessors were blinded. Only the trial administra-
tor and the data manager at the Nottingham Clinical Tri-
als Unit were aware of participants’ allocation.Participants and settings
The principal investigators of both recruiting centres com-
piled a list of prospective vitiligo patients (September 2011
to January 2012). Patient identification centres ran
searches in their databases using the following criteria:
diagnosis of vitiligo and age of 5 years old or older. A ded-
icated website (www.vitiligostudy.org.uk) was available for
the purpose of this trial. Participants with non-segmental,
spreading or stable vitiligo (confirmed by a dermatolo-
gist), affecting <25% of their body surface area, older
than 5 years old, were included in the trial. No therapy
for vitiligo in the previous two weeks and no other con-
current vitiligo treatments during the trial were allowed.
For each participant, up to three vitiliginous lesions
were chosen, preferably on three different anatomical
areas. Exclusion criteria were: segmental or universal
vitiligo, previous history of skin cancer, recent/concur-
rent radiotherapy, photosensitivity, use of immunosup-
pressive or photosensitive drugs, pregnant or lactating
women, major medical co-morbidities, and vitiligo lim-
ited to the genitalia only.
All participants (or their parent/legal guardian if a par-
ticipant was under the age of 16) provided written in-
formed consent before they entered the trial. In addition, a
second consent form was signed on completion of the
NB-UVB training session.Outcomes
The primary outcome measure for this pilot trial was
the proportion of eligible participants who were willing
to be randomised (number of randomised participants/
number of eligible participants at baseline).
The secondary outcomes were:
 Proportion of participants expressing interest in the
trial (number of participants pre-screened/number
of invitation sent) and fulfilling eligibility criteria
(number of participants eligible at baseline visit/
number of participants pre-screened).
 Withdrawal rates and missing data.
 Proportion of participants adhering to and satisfied
with the treatment (number of participants who
complied with the treatment regimen/total number
of randomised participants). Adherence was
monitored using all of the following parameters:○ Three to four treatment sessions per week.
○ At least one day should be left between consecutive
treatment sessions.
○ If a treatment session was missed due to side effects and
the treatment plan was resumed correctly, participants
were considered compliant with the treatment plan. Incidence of NB-UVB short-term adverse events
(erythema (Grade 1–4), pruritus, perilesional
hyperpigmentation, hypersensitivity reactions, cold
sores, dry skin).
 Proportion of participants and assessors for whom
the blinding of the allocated group (active/placebo)
was maintained.
Outcome measures for the main large trial were also
tested:
 Repigmentation rate of vitiliginous lesions presented
in percentage of repigmentation quartiles: negative–
0%, 1–24%, 25–49%, 50–74%, 75–100%. ConvaTec
transparencies were used to trace the lesions at
baseline and week 16 visits. These were measured by
using the ImageJ 1.47d (Image processing and
analysis in Java by the National Institute of Health,
USA; http://imagej.nih.gov/ij).
 Cessation of spreading of vitiligo during the past
year, i.e., no new vitiliginous lesions or no increase
in size of existing vitiliginous lesions in the last
12 months.
 Impact on the quality of life of participants:
Dermatology Life Quality Index (DLQI) [13] and
Children Dermatology Life Quality Index (CDLQI)
[14] on baseline and week 16 visits.
 Global improvement in vitiligo: 5-point Likert scale
(much worse; a bit worse; no change; a bit better;
much better) at week 16 visit.
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16 visit.
 Colour match of newly repigmented vitiliginous
lesions (bad, fair, or excellent). Patient and research
nurse were asked to rate the colour match of each
representative lesion at the week 16 visit. This
outcome was subjective.
Trial procedures
On receipt of a potential participant’s contact details, an
age-appropriate information sheet was sent and a member
of the research team made contact. Participants were pre-
screened over the telephone. A hospital visit for success-
fully pre-screened patients was booked. The initial trial
visit took approximately 1.5 to 2 hours and included a
training session on how to complete the treatment diary
and adjust treatment time accordingly to the erythema re-
sponse and what to do in case of short-term side effects.
Participants returned to the hospital the following day and
their Minimal Erythema Dose (MED) results were read.
Participants had to return to the hospital at week 8 and
week 16 (final face-to-face visit) (Figure 1).
Intervention
In the active group, two different hand-held NB-UVB de-
vices were explored: Dermfix 1000™ NB-UVB and Wald-
mann™ NB-UVB 109. The placebo device was identical to
the active device Dermfix 1000, with the only difference
being that a special plastic cover blocked the emission of
NB-UVB rays. The output of each of the hand-held de-
vices was tested before and after the trial.
Treatment plan and adherence
The treatment was self-administered by the participants
or their carers on alternate days, i.e., three to four times
a week but never on consecutive days. Each participant
received a personalised treatment plan according to his/
her Fitzpatrick skin type: I, II, III, and IV–VI (Table 1).
In addition, the results of the MED test-determined skin
type were compared to the dermatologist recorded skin
type. This was important in order to determine whether
or not the MED test was necessary for the future RCT,
or whether the treatment plan based on a dermatologist
recorded skin type alone was safe.
Participants’ adherence to the treatment was monitored
by reviewing their diaries. The number of treatment ses-
sions per week and treatment times were used as parame-
ters to monitor participants’ compliance.
Statistical analysis
Demographic characteristics of the participants, measures of
adherence to the treatment plan, and all other outcomes
data, including outcomes for the main RCT, were sum-
marised by descriptive statistics or frequency tables, stratifiedby active/placebo groups. No formal statistical analyses were
performed on outcome measures since this was a pilot study
to determine feasibility of a definitive trial. All analyses were
performed using Stata SE 11 and MS Excel 2007.
Sample size
This was a pilot study, with sample size being resource-
driven in terms of available participants in a reasonable
time-frame, for which no formal statistically based sample
size estimate was applicable. A minimum of 21 participants
from two recruitment sites was deemed appropriate to




In total, 97 people approached the research team, express-
ing an interest in this pilot trial (Figure 2). Forty-eight invi-
tation letters were sent to vitiligo patients who attended
dermatology departments at the Queen’s Medical Centre/
NHS Treatment Centre in Nottingham (31 patients) and
the Leicester Royal Infirmary (17 patients). We received 38
(response rate = 79% (38/48)) completed reply slips from
patients, who were willing to be contacted (Nottingham re-
sponse rate = 93.5% (29/31); Leicester response rate = 53%
(9/17)). In addition, two GP surgeries (one in Leicester and
one in Nottingham) sent 67 invitation letters. From these,
we received 28 completed reply slips (total response rate =
40% (28/67)). In addition, six more GP practices expressed
an interest in taking part in this trial. However, due to the
overwhelming response from the secondary care patients
and lack of time and resources for further recruitment,
these surgeries were asked not to send invitation letters.
In addition, the Vitiligo Society UK sent 74 invitation let-
ters to its members living in Nottingham, Leicester, and
Birmingham. Fourteen patients were interested in the trial
(response rate = 19% (14/74)). Finally, patients held on a
mailing list at the Centre of Evidence Based Dermatology
were also informed about the trial (n = 284).
In total, 55.6% (54/97) of people who expressed inter-
est in the trial were successfully pre-screened by tele-
phone and provisionally met the trial eligibility criteria;
83% of them (45/54) were willing to attend the baseline
visit and be randomised (Figure 2).
Due to time and financial constraints, only 29 of 45
potential participants were booked to attend a baseline
hospital visit on a “first come-first served” basis. All 29
potential participants who attended the baseline visit
were confirmed as being eligible and were subsequently
randomised into the trial (29/29; 100%) (Figure 3).
In total, 29 participants with 84 representative lesions
were randomised into the two groups (Table 2) at a ratio
of 2:1 (active: placebo). Within the active group, patients
were randomised to two different active devices (Figure 3).
Table 1 Summary of treatment schedules according to the participants’ skin type







I 15 sec +3 sec −3 sec 3 min 4 months
II 20 sec +4 sec −4 sec 4 min 4 months
III 25 sec +5 sec −5 sec 5 min 4 months
IV 30 sec +6 sec −6 sec 6 min 4 months
V 30 sec +6 sec −6 sec 6 min 4 months
VI 30 sec +6 sec −6 sec 6 min 4 months
2:1
Telephone call 
Discuss provisional eligibility for the trial; arrange clinic 
appointment; send participant information sheets (if not 
already received)
Screening/ Randomisation/Educational visit
Confirmation of  diagnosis
Eligibility check
MED test (consent for UVB treatment)
Data collection, pictures taken
Education on use of home devices / completion of 
diary / monitoring of side-effects
Active group Placebo group
Dermfix Waldmann
Telephone call: at 1 week and 
2 weeks
Face to face visit at 8 weeks: 
Outcomes assessment
Telephone call: at 12 weeks
Final face to face visit at 16 
weeks: photographs taken, 
lesions measured. Outcomes 
assessed. Exit interview
Approach letter sent from clinical team/patient 
identification centres
Participant returned reply slip to co-ordinating centre
Direct advertising
Participant contacted co-ordinating centre expressing 
an interest in the trial
Baseline
MED test results/Start date and treatment regimen 
confirmation
Age appropriate 
Participant Info Sheets sent
Explanation / consent
Figure 1 Flowchart of HI-Light trial configuration.







Vitiligo PSP participants n=248 
(overlap with Vitiligo Society)
Expression of interest:
Total n=97
Secondary care n=38/97 (39%)
Primary care n=28/97 (29%)








Potentially eligible n=54/97 (55.6%)
Booked at clinic for eligibility 
confirmation and baseline  
n=29/45 (65%)
Potentially eligible but 
unwilling to be randomised 
n=9/54 (17%)
Reasons: 
Risk of burning (22%)
Time consuming (11%)
Forthcoming holidays (11%)
Possible placebo group (11%)
Did not specified (45%)
Attended clinic, confirmed eligible 
and randomised 
n=29/29 (100%)
6 more GP surgeries 
were declined 
participation due to 
limited capacity
Potentially eligible and willing to be 
randomised n=45/54 (83%)
Secondary care n=21/45 (47%)
Primary care n=10/45 (22%)
Vitiligo Society/PSP n=8/45 (17.5%)
Google/other sources n=6/45 (13.5%)
Not fully pre-screened
n=16/97 (16.4%)




Figure 2 Summary of recruitment sources into the HI-Light trial for vitiligo.
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Three of 29 participants (10%) withdrew from the treat-
ment (two patients from the active group and one from
placebo group). The reasons for withdrawals were that
the treatment was too time consuming (3%; 1/29) and
the lack of improvement in vitiligo (7%; 2/29). Only one
(3%) participant was lost to follow-up (Figure 3).
Missing data
All participants, except one who was lost to follow-up,
completed the end of study questionnaire in full (28/29;
96.5%). The DLQI and PBI questionnaires at baselineand week 16 were completed by 96.5% (28/29) of partici-
pants also; at baseline one participant did not complete the
questionnaires. One missing diary and week 16 question-
naire (3%; 1/29) belonged to the patient lost to follow-up.
The research team made every effort possible to contact
and find the patient, including reaching out to his regular
GP. Unfortunately, neither the diary nor the device were
recovered.
Adherence
All but one treatment diary (28/29; 97%) were returned












Too time consuming (7%)
No improvement (3%)
Week 16 final visit
n=25/29 (86%)
Week 8 hospital visit n=29(100%)
Placebo group
n=10




Figure 3 Flow-diagram of randomised participants into the HI-Light trial.
Eleftheriadou et al. Trials 2014, 15:51 Page 7 of 12
http://www.trialsjournal.com/content/15/1/51four-month treatment course, of which 84% (21/25) ad-
ministered phototherapy at home three to four times a
week and reduced treatment time correctly. Common
mistakes were: no treatment time reduction (6/25; 24%) or
incorrect time reduction (1/25; 4%) following a missed
treatment session. These minor deviations from the treat-
ment schedule did not result in serious side effects.
Satisfaction with the treatment
Participants in the active group were more likely to be
satisfied with their treatment than participants allocated
to the placebo group (31.5% versus 20%). The majority
of participants in both groups said they would use thehand-held device again and recommend it to others
(68% (19/28) and 64% (18/28), respectively).
Both active devices (Dermfix™ and Waldmann™) re-
ceived the following positive comments: easy to use, port-
able, compact, convenient to operate at home, no need of
coming to the hospital, easy to perform, and flexible. Add-
itional positive comments on the Dermfix devices related
to its convenient shape.
Side effects
Erythema grade 1 and 2 was reported in 27% (8/29) and
13% (4/29) of participants, respectively, in the active
group. Only one patient reported erythema grade 3 (3%).
Table 2 Baseline characteristics of participants of HI-Light trial
Baseline characteristics All groups Active group Placebo group
Number of participants 29 19 10
Age range (years) 5–71 5–71 13–51
Adult/child 23/6 14/5 9/1
Age mean (years); SD 31.7 ± 17.9 27.63 ± 18.6 39.4 ± 13.5
Adults 38.6 ± 14.8 38 ± 15.8 42.3 ± 10.85
Children 10.25 ± 3.5 9.9 ± 3.6 13 ± n/a
Sex (female/male) 15/14 10/9 5/5
Ethnicity:
White British 20/29 (69%) 12/19 (64%) 8/10 (80%)
Mixed 1/29 (3.5%) 1/19 (5%) None
Black/Black Caribbean 2/29 (7%) 2/19 (11%) None
Indian 2/29 (7%) 1/19 (5%) 1/10 (10%)
Pakistani 1/29 (3.5%) 1/19 (5%) None
Asian 2/29 (7%) 1/19 (5%) 1/10 (10%)
Other ethnic group 1/29 (3.5%) 1/19 (5%) None
Duration of vitiligo (years)
Mean ± SD (min; max) 12.28 ± 9.67 (min = 2; max = 33) 11.36 ± 10.12 (min = 2; max = 33) 14.01 ± 8.5 (min = 5; max = 28)
Vitiligo activity per participant (overall)
Stable 6 3 3
Spreading 19 14 5
Repigmenting 4 2 2
BSA% covered by vitiligo Mean ± SD (min; max) 8.83 ± 6.19 (min = 2; max = 25) 9.84 ± 5.96 (min = 3; max = 25) 6.9 ± 6.17 (min = 2; max = 21)
Number of lesions 84 56 28
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mentation around the lesions (10% (3/29)) and dry skin
(10% (3/29)), cold sores (3% (1/29)). In the placebo group,
two patients reported erythema grade 1 (6% (2/29)). No
other side effects were reported in the placebo group.
Repigmentation
At baseline, the mean size of lesions in the active and
placebo groups were 15.42 cm2 (SD: ± 20.2 cm2) and
20.54 cm2 (SD: ± 19.4 cm2), respectively. At the week 16
hospital visit, the mean size of lesions in the active and
placebo groups were 14.43 cm2 (SD: ± 18 cm2) and
21 cm2 (SD: ± 20.85 cm2), respectively.
High grade repigmentation (75–100%) was noted in
12% (1/17) of participants in the active group, compared
to none in the placebo group. In the active group, 75%
(29/39) of all lesions showed some repigmentation com-
pared to 39% of lesions in the placebo group. Overall,
the anatomical sites which responded best to treatment
were the face and neck (Tables 3, 4, 5).
Cessation of spreading of vitiligo
In the active group, 44% of lesions (22/50) remained stable
throughout the trial compared to 72% (13/28) of lesions inthe placebo group; 27% (11/50) and 22% (4/18) of stable
lesions started repigmenting in the active and the placebo
groups, respectively.
Global improvement in vitiligo
Patients rated their vitiligo as being “much better” in
17% (3/18) of cases in the active group compared to
none in the placebo group. Similarly, 23% (4/17) of re-
search nurses and independent outcome assessors rated
patients’ vitiligo as being “much better” in the active
group compared to 0% in the placebo group.
Colour match of vitiliginous patches
In the active group, around one third of newly repig-
mented lesions were rated as good to excellent by pa-
tients, research nurses, and independent assessors (30%
(16/53), 32% (16/50), and 24% (12/50), respectively). On
the other hand, no one rated newly repigmented lesions
as good or excellent in the placebo group.
Quality of life
There was a little change in the DLQI scores from baseline
(active groups mean ± SD: 2.8 ± 3.2, min = 0, max = 6; pla-
cebo group mean ± SD: 3.8 ± 3.2, min = 0, max = 10) to
Table 3 Mean percentage of repigmentation after 16 weeks of treatment with home phototherapy per participant
Number of
participants in:
Mean % repigmentation after 16 weeks of treatment per participant
Negative–0 1–24 25–49 50–74 75–100 Total
Active group 6 (35%) 8 (47%) 1 (6%) 0 2 (12%) 17
Placebo group 4 (40%) 6 (60%) 0 0 0 10
Total 10 (37%) 14(52%) 1 (4%) 0 2 (7%) 27
When analysing the overall treatment response per participant, mean percentage of repigmentation of all representative lesions for each participant was
estimated. This was done by simply finding the total difference in size, of all lesions at baseline and week 16 in cm2. The results were afterwards converted into
percentages and allocated to one of the five groups (negative–0%, 1–24%, 25–49%, 50–74%, 75–100%).
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max = 7; placebo group mean ± SD: 3.7 ± 3.8, min = 0,
max = 12) in both the active and placebo groups, sug-
gesting that the treatment had little impact on quality of
life. The CDLQI was not analysed due to insufficient
numbers of children in the trial.
Benefit evaluation in vitiligo
There was no difference between the active and placebo
groups in the PBI index. The mean PBI for the active group
(17 participants) was 0.92 (SD: ± 1.16; min = 0; max = 3.68)
and mean PBI for the placebo group (10 participants) was
0.91 (SD: ± 0.99; min = 0; max = 3.26). Both groups re-
ported a PBI of approximately 1 (“slight benefit”).
Success of blinding
At the end of the trial, 70% (19/27) of participants and 40%
(16/27) of research nurses guessed treatment allocation cor-
rectly. The main reasons for unblinding of the research
nurses were erythema (30% (3/10)) and improvement in
vitiligo (60% (6/10)) in the active group, and lack of treat-
ment response (100% (6/6)) in the placebo group.
Minimal erythema dose
In only half of patients (55% (16/29)), the starting dose
as determined by the MED test was the same as that es-
timated by a dermatologist based on skin type alone. In
17% (6/29) of participants, the MED test results showedTable 4 Repigmentation in the active group for each anatom
Face/neck Trunk
Number of participants* 6 6
Repigmentation:
Negative–0% 2 (33%) 3 (50%)
1–24% 1 (17%) 2 (33%)
25–49% 1 (17%) 0
50–74% 0 0
75–100% 2 (33%) 1(17%)
Baseline: mean lesion size (cm2 ± SD) 75.4 ± 7.4 13 ± 15
16 week: mean lesion size (cm2 ± SD) 47.4 ± 4.4 13.7 ± 1
*One lesion per anatomical site per participant was analysed. If two or more lesions
chosen. If no lesions were available on the right side, then the lesion, which repigmthat their skin was more sensitive to sunlight than deter-
mined by a dermatologist. In 24% (7/29) of participants,
the MED results were higher than the ones determined
by dermatologists allowing them to be prescribed a
higher dose of NB-UVB.
Discussion
The majority of clinical treatment recommendations for
vitiligo are based on small, inconclusive trials, specialist
consensus, and data from other skin diseases [1,2]. Per-
haps unsurprisingly, patients often feel abandoned and
believe that they do not receive adequate support from
their doctors [16].
The HI-Light pilot trial was the first trial evaluating
the safety of using hand-held phototherapy at home and
testing the feasibility of conducting the first national
multi-centre RCT on home hand-held phototherapy for
vitiligo. Although this was not an efficacy trial, this pilot
trial was a crucial preliminary step to support a grant
application for a national multi-centre RCT and to de-
velop a training package on home targeted phototherapy
for vitiligo.
Summary of the main findings
Recruitment into the trial went surprisingly well. The
target number of participants was exceeded easily and
the recruitment period lasted only three months instead
of six.ical site per participant
Anatomical site
Upper limbs Lower limbs Hands/feet
13 11 3
3 (22%) 2 (18%) 0
8 (62%) 7 (64%) 2 (67%)
1 (8%) 2 (18%) 1 (33%)
0 0 0
1 (8%) 0 0
.9 11.2 ± 10.9 21 ± 29.1 18.9 ± 25.7
7.4 10.3 ± 9.6 20.6 ± 25.8 22.6 ± 26.6
were available on the same anatomical site, the lesion on the right side was
ented the most, was included in the analysis.
Table 5 Repigmentation in the placebo group for each anatomical site per participant
Anatomical site
Face/neck Trunk Upper limbs Lower limbs Hands/feet
Number of participants* 5 1 8 5 4
Repigmentation:
Negative–0% 3 (60%) 0 3 (37%) 5(100%) 2 (50%)
1–24% 1 (20%) 1(100%) 5 (63%) 0 2 (50%)
25–49% 1 (20%) 0 0 0 0
50–74% 0 0 0 0 0
75–100% 0 0 0 0 0
Baseline: mean lesion size (cm2 ± SD) 10.7 ± 5.6 34.8 22.6 ± 18.4 22.6 ± 24 20.9 ± 8.8
16 week: mean lesion size (cm2 ± SD) 11.3 ± 7 28.2 23.2 ± 21.6 26.1 ± 27.2 20.7 ± 6.4
*One lesion per anatomical site per participant was analysed. If two or more lesions were available on the same anatomical site, the lesion on the right side was
chosen. If no lesions were available on the right side, then the lesion, which repigmented the most, was included in the analysis.
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to the hospital visit proved to be very successful. Pre-
screening participants over the phone saved time and re-
sources, considering that both a dermatologist and a re-
search nurse had to be present during the initial hospital
visit and a room had to be booked in a busy dermatology
clinic for each potential participant.
Only 10% of participants withdrew from the trial com-
pared to the previously reported 20% in a trial on hos-
pital phototherapy [17]. The findings of the trial suggest
that patients with vitiligo are very keen to take part in
trials on home light phototherapy using hand-held de-
vices. The main reason for this was the fact that the
treatment was self-administered at home, allowing flexi-
bility around days and times for administration.
The training session and materials on how to self-
administer home phototherapy were comprehensive, ad-
equate, and easy to follow, as demonstrated by only one
incident of erythema grade 3 and high levels of adherence
to the treatment plan (86%). Erythema grades 1 and 2 are
generally considered acceptable and indicate response to
light therapy. Surprisingly, two patients in the placebo
group also reported erythema grade 1. The most likely ex-
planation for this might be confusion of erythema grade 1
with erythema caused by normal warming up of the device
during treatment.
Satisfaction with the treatment in both active and pla-
cebo groups only differed slightly (31.5% versus 20%).
Further, active and placebo groups reported only a
“slight benefit” from the treatment and, in general, did
not show any changes in their quality of life. This comes
as no surprise as the treatment period was clinically in-
adequate given the limited duration of this pilot trial.
On the other hand, 75% of lesions in the active groups
showed some degree of repigmentation. In the clinical
setting, this is usually an indication to continue photo-
therapy treatment [1].Limitations of this trial
The main limitations of this trial were the short treat-
ment period and the small sample size, although it was
not designed to be an efficacy trial. Nevertheless, four
months was adequate to capture initial treatment re-
sponse, if any, and therefore provide an indication as to
whether or not treatment should be continued.
Although the secondary care recruitment was excel-
lent, this is likely to be lower in centres where there is
no adequate research nurse support.
The unsuitability of the ConvaTec transparencies for
skin mapping of vitiliginous lesions was a potential source
of measurement error in the repigmentation measure-
ments. As this pilot trial did not seek to answer efficacy
questions on home hand-held phototherapy, the above did
not affect the validity of this trial.
Recommendations for future trials
In order to inform future trials on home hand-held photo-
therapy, the following recommendations are provided:
Recommendation 1: Recruitment through primary care
(General Practice surgeries). Primary care is likely to be
the main source of potential participants (especially for
early and limited disease). In addition, in order to reduce
the burden on clinic space and availability of investiga-
tors, it is recommended that potential participants are
pre-screened over the telephone.
Recommendation 2: Skin mapping using transparencies.
Skin mapping captures the three-dimensional character of
vitiliginous lesions, does not require standardisation, spe-
cific body positioning, or expensive equipment. It is also
easy to replicate and relatively cheap. On the other hand,
the pattern of repigmentation (perifollicular or diffuse),
and the colour match of newly repigmented lesions made
it difficult to clearly identify the edges of the vitiliginous
area. Based on the above, it is important to identify a suit-
able (very thin, flexible, and not shiny) transparency,
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the need for manual transfer. Good lighting in the clinic
room and contouring of the vitiliginous lesion with a sur-
gical skin mapping pen are recommended.
Recommendation 3: Outcomes for the main trial. On
the basis of the results of the pilot trial, the following
outcomes are recommended to be included in the main
trial: repigmentation, patient reported success, cessation
of spreading of vitiligo, and impact on quality of life of
vitiligo patients, amongst others that researchers deem ap-
propriate for their trial. Also, based on the above recom-
mendation (2), researchers should consider choosing
patient-reported success rather than repigmentation as a
primary outcome. Although the former is a subjective out-
come, perhaps it better captures several aspects of repig-
mentation such as pattern of repigmentation, colour
match of newly repigmented lesions, and percentage of
repigmentation (size of vitiliginous lesions).
Recommendation 4: MED testing is recommended for
future trials on home hand-held phototherapy and is ne-
cessary to ensure patients’ safety and appropriate NB-
UVB dose administration.
Recommendation 5: A training DVD on how to use
hand-held devices at home has been produced in order to
standardise this intervention and ensure consistency in
the training provided (www.nottingham.ac.uk/research/
groups/cebd/index.aspx). The training package developed
for this trial proved to be comprehensive, well understood,
and safe.
Recommendation 6: Inclusion of active treatments in
all groups would help to avoid unblinding resulting from
differential treatment response. Although it is possible
to mask the treatment allocation, this is likely to be
compromised and should therefore be planned for.Conclusions
In light of newly emerging evidence that early treatment
of vitiliginous lesions seems to be effective [3-5], a trial
utilising hand-held phototherapy at home seems an ap-
propriate way forward.
The HI-light pilot trial showed that the training on
hand-held phototherapy was comprehensive and well tol-
erated. This intervention seems to be safe for the home-
treatment of vitiligo in isolated areas of the body in both
adults and children.
In conclusion, the results of this pilot trial strongly sug-
gest that a national multi-centre RCT involving home
hand-held phototherapy is both feasible and acceptable to
patients and clinicians. It would address an important area
of unmet need, potentially providing a useful treatment
strategy for patients with limited/early disease and assist
future research into the treatment of vitiligo, based on the
topics of importance for patients and clinicians [12].Abbreviations
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